John Shipp, MD
Ophthalmology · Jackson, MSNPI 1538379789
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.6%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Rxsight Inc accounts for 60.1% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $6,541 and has fallen 90.9% since, to $595 in 2025. Among ophthalmology clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 239 payments — averaging $42.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$6K
- Alcon$1K
- Mallinckrodt Hospital Products Inc.$537
- AbbVie$420
- Sight Sciences, Inc.$312
- Johnson & Johnson Surgical Vision, Inc.$288
- plus $1K from 18 others
Across 2 payments — averaging $10,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$20K
What the payments were for
- Consulting fees$5,70057%
- Speaking & faculty fees$260%
- Food & beverage$4,34743%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 12 | $6,052 |
| Alcon | 65 | $1,040 |
| Mallinckrodt Hospital Products Inc. | 31 | $537 |
| AbbVie(2 entities) | 24 | $420 |
| Sight Sciences, Inc. | 13 | $312 |
| Johnson & Johnson Surgical Vision, Inc. | 12 | $288 |
| Ocular Therapeutix, Inc. | 13 | $252 |
| Eyepoint US, Inc. | 16 | $217 |
| Ivantis, Inc | 7 | $176 |
| Amgen(2 entities) | 10 | $171 |
| Oyster Point Pharma, Inc. | 4 | $65 |
| Iridex Corporation | 2 | $62 |
| Bausch & Lomb Americas Inc. | 3 | $61 |
| Biotissue Holdings Inc. | 4 | $57 |
| Rayner Intraocular Lenses Limited | 4 | $55 |
| Harrow Eye, LLC | 3 | $53 |
| Omeros Corporation | 4 | $51 |
| Glaukos Corporation | 2 | $41 |
| ANI Pharmaceuticals, Inc. | 2 | $39 |
| NEW World Medical,inc. | 3 | $37 |
| Sun Pharmaceutical Industries Inc. | 2 | $28 |
| Dompe US, Inc. | 1 | $20 |
| Carl Zeiss Meditec USA, Inc. | 1 | $18 |
| Eyevance Pharmaceuticals LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,072 in reported general payments places this provider in the 90th percentile of 150 ophthalmology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 67 | $27,076 |
| RestasisCyclosporine | 14 | $16,059 |
| CombiganBrimonidine Tartrate/Timolol | 65 | $14,262 |
| ProlensaBromfenac Sodium | 32 | $10,564 |
| Loteprednol Etabonate | 67 | $7,873 |
| Fluorometholone | 109 | $7,213 |
| Alphagan PBrimonidine Tartrate | 13 | $6,274 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $4,495 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 124 | $2,550 |
| Latanoprost | 323 | $2,266 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 30 | $2,237 |
| Prednisolone Acetate | 48 | $1,931 |
| MoxifloxacinMoxifloxacin Hcl | 68 | $1,409 |
| Ketorolac Tromethamine | 57 | $895 |
| Timolol Maleate | 82 | $480 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $420 | $63,671159 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 150 ophthalmology providers in Mississippi.
Other ophthalmology in Jackson
- Heather HancockJackson$39K
- Mark KoskoJackson$27K
- Kirk JeffreysJackson$9K
- Lee JonesJackson$8K
- Albert WilliamsJackson$6K
- Younghyun OhJackson$5K
- Farrah NewmanJackson$4K
- Taylor SmithJackson$4K
- Cassie ConfaitJackson$4K
- Curtis WhittingtonJackson$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.